Karl Csaky
Ophthalmology · Dallas, TXNPI 1144375122
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $300,854 of the $426,138 with a category attached, or 70.6%. 21 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 27.3% of the total. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $1821.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$117K
- Genentech, Inc.$62K
- Carl Zeiss Meditec, Inc.$40K
- Genentech USA, Inc.$38K
- Janssen Research & Development, LLC$27K
- Boehringer Ingelheim International GmbH$26K
- plus $117K from 15 others
Across 360 payments — averaging $12,530 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.4M
- Genentech, Inc.$606K
- AstraZeneca$470K
- Boehringer Ingelheim$320K
- Regeneron$228K
- Janssen Research & Development, LLC$199K
- plus $323K from 5 others
What the payments were for
- Consulting fees$300,85471%
- Speaking & faculty fees$77,05218%
- Travel & lodging$42,14810%
- Food & beverage$6,0841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 48 | $116,531 |
| Genentech, Inc. | 43 | $61,782 |
| Carl Zeiss Meditec, Inc. | 4 | $40,424 |
| Genentech USA, Inc. | 30 | $37,547 |
| Janssen Research & Development, LLC | 9 | $27,304 |
| Boehringer Ingelheim International GmbH | 17 | $25,760 |
| Heidelberg Engineering, Inc. | 5 | $18,089 |
| AbbVie(2 entities) | 14 | $16,980 |
| Roche Products Limited | 3 | $15,617 |
| Merck | 14 | $11,807 |
| Shire North American Group Inc | 4 | $8,630 |
| Astellas Pharma Global Development | 2 | $7,858 |
| Apellis Pharmaceuticals, Inc. | 3 | $7,193 |
| Regeneron | 13 | $6,992 |
| Novartis | 5 | $6,519 |
| Biocryst Pharmaceuticals, Inc. | 4 | $5,263 |
| Janssen Global Services, LLC | 9 | $4,988 |
| Astellas Pharma Europe Ltd | 1 | $3,126 |
| Bausch & Lomb Americas Inc. | 2 | $3,048 |
| Sanofi US Services Inc. | 1 | $558 |
| Ocular Therapeutix, Inc. | 3 | $124 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$60,356
- Non-Covered Product$52,413
- CIRRUS HD-OCT$40,424
- Spectralis$18,001
- Lucentis$11,825
- Izervay$10,941
- TAKHZYRO$8,500
- VEOPOZ$6,611
- Creon$1,550
- OZURDEX$993
- SUSVIMO$780
- Syfovre$153
How this compares
$426,138 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Dallas
- Oluwatosin SmithDallas$1.5M
- Davinder GroverDallas$705K
- Ashkan AbbeyDallas$559K
- Jeffrey WhitmanDallas$190K
- Robert WangDallas$144K
- Arvind NeelakantanDallas$90K
- Michael SingerSan Antonio$1.8M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Christina WengHouston$676K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.